Actym Therapeutics, Inc.

Actym Therapeutics is a clinical-stage biopharmaceutical company focused on transforming cancer treatment. They have developed a proprietary novel drug modality called the STACT™ biological platform, which harnesses the power of a genetically modified bacterial vehicle to deliver multiple therapeutic payloads directly to the disease site. This approach allows for targeted anti-tumor effects by exploiting TME-specific metabolites, enabling the bacterial vehicle and therapeutic payloads to selectively enrich in tumors. Their flagship drug candidate, ACTM-838, utilizes the STACT™ platform to deliver IL-15plex and eSTING to the TME.

Actym’s technology is designed to overcome the challenges posed by the immunosuppressive tumor microenvironment (TME), which often limits the efficacy of conventional cancer therapies. Their approach offers a promising safety profile by minimizing systemic side effects and reducing the impact on healthy tissues. Actym's innovative approach leverages the unique properties of attenuated S. Typhimurium, a type of bacteria, to selectively target and modulate the TME, opening new possibilities for cancer treatment.

Actym Therapeutics does not specify any information about their job flexibility on their website.

Actym Therapeutics offers a comprehensive benefits package designed to support its employees' well-being. This includes competitive compensation, stock option grants, comprehensive health insurance (medical, dental, and vision), a 401K retirement plan, short- and long-term disability coverage, paid time off, holidays, and sick days, life and accidental death and dismemberment insurance, and a positive and supportive company culture.

Actym Therapeutics is a clinical-stage biopharmaceutical company dedicated to revolutionizing cancer treatment through its innovative drug modality, the STACT™ biological platform. This platform utilizes genetically modified bacteria as a safe, systemically administered vehicle to deliver multiple therapeutic payloads directly to the tumor microenvironment, where they are amplified and produced locally. This targeted approach aims to overcome the challenges of the immunosuppressive tumor microenvironment, achieving a new level of therapeutic impact for cancer patients across multiple tumor types.

Actym Therapeutics cultivates a dynamic and collaborative work environment that values scientific innovation and the pursuit of excellence. They prioritize a culture of commitment, accountability, quality, respect, and collaborative decision-making. This is fostered through open communication, the sharing of ideas, and a willingness to learn from both successes and failures. Actym recognizes their employees as their greatest asset and strives to provide a supportive and inclusive atmosphere that allows everyone to contribute their unique talents and perspectives.

Actym Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace where all employees feel valued, respected, and empowered to contribute their unique perspectives and talents. They strive to create a culture that embraces diversity in all its forms, including race, gender, ethnicity, sexual orientation, gender identity, religion, age, and disability. Actym believes that a diverse and inclusive workforce leads to a more innovative and successful organization, and they actively seek to attract, retain, and develop talent from all backgrounds.